Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

iBio (IBIO) Operating Expenses (2016 - 2025)

Historic Operating Expenses for iBio (IBIO) over the last 17 years, with Q4 2025 value amounting to $9.4 million.

  • iBio's Operating Expenses rose 10448.15% to $9.4 million in Q4 2025 from the same period last year, while for Dec 2025 it was $25.8 million, marking a year-over-year increase of 6173.83%. This contributed to the annual value of $19.0 million for FY2025, which is 1271.13% up from last year.
  • iBio's Operating Expenses amounted to $9.4 million in Q4 2025, which was up 10448.15% from $6.1 million recorded in Q3 2025.
  • iBio's Operating Expenses' 5-year high stood at $10.6 million during Q4 2022, with a 5-year trough of $3.6 million in Q2 2024.
  • Its 5-year average for Operating Expenses is $6.5 million, with a median of $5.7 million in 2025.
  • In the last 5 years, iBio's Operating Expenses skyrocketed by 15981.33% in 2021 and then tumbled by 5747.66% in 2023.
  • Over the past 5 years, iBio's Operating Expenses (Quarter) stood at $7.2 million in 2021, then skyrocketed by 46.22% to $10.6 million in 2022, then tumbled by 57.48% to $4.5 million in 2023, then increased by 2.74% to $4.6 million in 2024, then soared by 104.48% to $9.4 million in 2025.
  • Its Operating Expenses stands at $9.4 million for Q4 2025, versus $6.1 million for Q3 2025 and $5.4 million for Q2 2025.